Gast ::
| Hauptseite > Publikationsdatenbank > 52gMn(II)-Labelled PSMA-ligands as bimodal PET/MR imaging probes > print |
| Hauptseite > Publikationsdatenbank > 52gMn(II)-Labelled PSMA-ligands as bimodal PET/MR imaging probes > print |
| 001 | 1027702 | ||
| 005 | 20240625201957.0 | ||
| 024 | 7 | _ | |a 10.1016/S0969-8051(22)00335-3 |2 doi |
| 024 | 7 | _ | |a 0969-8051 |2 ISSN |
| 024 | 7 | _ | |a 1872-9614 |2 ISSN |
| 037 | _ | _ | |a FZJ-2024-04012 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Strecker, Jonas |0 P:(DE-Juel1)186668 |b 0 |u fzj |
| 111 | 2 | _ | |a 24th International Symposium on Radiopharmaceutical Sciences |g ISRS2022 |c Nantes |d 2022-05-29 - 2022-06-03 |w France |
| 245 | _ | _ | |a 52gMn(II)-Labelled PSMA-ligands as bimodal PET/MR imaging probes |
| 260 | _ | _ | |c 2022 |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a Other |2 DataCite |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a LECTURE_SPEECH |2 ORCID |
| 336 | 7 | _ | |a Conference Presentation |b conf |m conf |0 PUB:(DE-HGF)6 |s 1719300737_5390 |2 PUB:(DE-HGF) |x After Call |
| 520 | _ | _ | |a Introduction: By combining the advantages of two or more complementaryimaging modalities, hybrid techniques like PET/MR allowfor sequential or simultaneous acquisition of anatomical and molecularinformation. Although the alignment of hybrid datasets acquiredin simultaneous PET/MR has been shown to be more accurate, thereis still a lack of probes for bimodal PET/MR imaging. Radiolabellingwith isotopic mixtures of 52gMn/55Mn provides direct access to suchprobes1,2, as the paramagnetic 55Mn acts as an MRI contrast agent3,while 52gMn is a promising +-emitter for PET imaging (t½ = 5.6 d, E+,end = 0,58 MeV). In the present work, the PSMA-selective moiety Glu-C(O)-Lys was functionalized by CuAAC click reaction with the chelatortrans-1,2-diaminocyclohexane-N,N,N`,N`-tetraacetic acid (CDTA)for Mn complexation and radiolabeling with 52gMn. In addition, thestability of the novel PET/MR probe was evaluated by preliminary invitro studies.Materials and Methods: Following its production by the52Cr(p,n)52gMn nuclear reaction, 52gMn was separated from the Crtarget using anion exchange chromatography. To this end, the Crtarget was dissolved in 2 m HCl, which was then evaporated todryness. The residue was dissolved in MeOH/conc. HAc (1:1) andtrapped on an AG-MP1 anion exchange column. The column waswashed with 30 mL MeOH/conc. HAc. (1:1) at 44°C and [52gMn]MnCl2was eluted with 3 m HCl.The CDTA ligand was synthesized using a modification of a previouslypublished method4 and coupled to the PSMA-selective Glu-C(O)-Lys pharmacophore by the copper(I)-catalyzed alkyne-azidecycloaddition (CuAAC) click reaction.The functionalized CDTA-ligand (2.5 mg) was dissolved in 0.1 mNaOAc buffer (pH 6) and treated with no-carrier added [52gMn]MnCl2for 30 min at ambient temperature, and the radiolabelled productwas subsequently isolated by HPLC.The stability of the PET/MR probe in the presence of human serumwas measured in HBS buffer at 37°C and analysed by HPLC.Results and Conclusion: No-carrier added 52gMn was isolatedfrom the Cr target with a separation yield of 93%. An improved labellingprotocol for the CDTA functionalized PSMA-selective ligand wasestablished, yielding a radiochemical yield of 50 % (based on HPLCanalysis of the crude product). After 24 h, 28.2% of the complex wasstill intact justifying further evaluation by in vivo animal studies.References:[1] Thomas G. et al. Innovative Magnetic Nanoparticles for PET/MRIBimodal Imaging. ACS Omega. 2019, 4, 2637-2648[2] de Rosales R.T.M. Potential clinical applications of bimodalPET-MRI or SPECT-MRI agents J. Label Compd. Radiopharm. 2014,57, 298–303[3] Glover, P., Mansfield, S. P. Limits to magnetic resonance microscopy.Reports Prog. Phys. 2002, 65, 1489.[4] Vanasschen, C., Brandt, M., Ermert, J., Coenen, H. H. Radiolabellingwith isotopic mixtures of 52g/55Mn(II) as a straight route to stablemanganese complexes for bimodal PET/MR imaging. Dalt. Trans.2016, 45, 1315–1321. |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Spahn, Ingo |0 P:(DE-Juel1)131849 |b 1 |u fzj |
| 700 | 1 | _ | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 2 |e Corresponding author |u fzj |
| 700 | 1 | _ | |a Giesen, Kai |0 P:(DE-Juel1)171718 |b 3 |
| 700 | 1 | _ | |a Gülez, Salim |0 P:(DE-HGF)0 |b 4 |
| 773 | _ | _ | |a 10.1016/S0969-8051(22)00335-3 |0 PERI:(DE-600)1498538-X |y 2022 |g Vol. 108-109, p. S157 - S158 |x 0969-8051 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027702/files/1-s2.0-S0969805122003353-main.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027702/files/1-s2.0-S0969805122003353-main.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027702/files/1-s2.0-S0969805122003353-main.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027702/files/1-s2.0-S0969805122003353-main.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027702/files/1-s2.0-S0969805122003353-main.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:1027702 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)186668 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)131849 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)166419 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-08-22 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NUCL MED BIOL : 2022 |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-22 |
| 915 | _ | _ | |a No Peer Review |0 StatID:(DE-HGF)0020 |2 StatID |b ASC |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-22 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-22 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-22 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 980 | _ | _ | |a conf |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|